Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures

Dow Jones00:11

By Christopher Kuo

Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates.

Shares of the biotechnology company fell 15% on Friday to $1.41. The company's shares are down 25% year to date.

The company on Thursday posted a loss of $8.3 million, or 3 cents a share, compared with a loss of $426.1 million, or $1.44 a share, a year earlier.

Adjusted earnings came in at a loss of 12 cents a share, in line with estimates by analysts, according to FactSet.

Revenue remained steady year over year at $37.2 million. Analysts expected $39.9 million.

Instrument revenue, particularly for its Vega system for DNA sequencing, was lower than expected, said Chief Executive Christian Henry. The decrease in shipments of Vega systems was driven by lighter demand in the U.S., where academic funding remains under pressure.

The company's revenue in Asia-Pacific declined 16% year over year, Henry said, as Chinese service providers wait for the launch of its SPRQ-Nx product.

For 2026, the company expects revenue to range from $165 million to $175 million. Analysts expect $171.5 million.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 08, 2026 12:11 ET (16:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634517463?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 00:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634517463","market":"other","top_or_hot":-1,"title":"Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates. \n</p>\n<p>\n  Shares of the biotechnology company fell 15% on Friday to $1.41. The company's shares are down 25% year to date. \n</p>\n<p>\n  The company on Thursday posted a loss of $8.3 million, or 3 cents a share, compared with a loss of $426.1 million, or $1.44 a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at a loss of 12 cents a share, in line with estimates by analysts, according to FactSet. \n</p>\n<p>\n  Revenue remained steady year over year at $37.2 million. Analysts expected $39.9 million. \n</p>\n<p>\n  Instrument revenue, particularly for its Vega system for DNA sequencing, was lower than expected, said Chief Executive Christian Henry. The decrease in shipments of Vega systems was driven by lighter demand in the U.S., where academic funding remains under pressure. \n</p>\n<p>\n  The company's revenue in Asia-Pacific declined 16% year over year, Henry said, as Chinese service providers wait for the launch of its SPRQ-Nx product. \n</p>\n<p>\n  For 2026, the company expects revenue to range from $165 million to $175 million. Analysts expect $171.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 12:11 ET (16:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Biosciences Shares Fall Amid 1Q Revenue Pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 00:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates. \n</p>\n<p>\n  Shares of the biotechnology company fell 15% on Friday to $1.41. The company's shares are down 25% year to date. \n</p>\n<p>\n  The company on Thursday posted a loss of $8.3 million, or 3 cents a share, compared with a loss of $426.1 million, or $1.44 a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at a loss of 12 cents a share, in line with estimates by analysts, according to FactSet. \n</p>\n<p>\n  Revenue remained steady year over year at $37.2 million. Analysts expected $39.9 million. \n</p>\n<p>\n  Instrument revenue, particularly for its Vega system for DNA sequencing, was lower than expected, said Chief Executive Christian Henry. The decrease in shipments of Vega systems was driven by lighter demand in the U.S., where academic funding remains under pressure. \n</p>\n<p>\n  The company's revenue in Asia-Pacific declined 16% year over year, Henry said, as Chinese service providers wait for the launch of its SPRQ-Nx product. \n</p>\n<p>\n  For 2026, the company expects revenue to range from $165 million to $175 million. Analysts expect $171.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 12:11 ET (16:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PACB","symbol_name":"Pacific Biosciences of Californi","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634517463","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634517463","pubTimestamp":1778256660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates.Shares of the biotechnology company fell 15% on Friday to $1.41. The company's shares are down 25% year to date.The company on Thursday posted a loss of $8.3 million, or 3 cents a share, compared with a loss of $426.1 million, or $1.44 a share, a year earlier.Adjusted earnings came in at a loss of 12 cents a share, in line with estimates by analysts, according to FactSet.Revenue remained steady year over year at $37.2 million. Analysts expected $39.9 million.Instrument revenue, particularly for its Vega system for DNA sequencing, was lower than expected, said Chief Executive Christian Henry. The decrease in shipments of Vega systems was driven by lighter demand in the U.S., where academic funding remains under pressure.The company's revenue in Asia-Pacific declined 16% year over year, Henry said, as Chinese service providers wait for the launch of its SPRQ-Nx product","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PACB":"Pacific Biosciences of Californi","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","BK4588":"碎股"},"translate_title":"太平洋生物科学公司股价因第一季度收入压力而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACB":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Pacific Biosciences of California shares fell after the company posted first-quarter revenue below Wall Street estimates. \n\n\n  Shares of the biotechnology company fell 15% on Friday to $1.41. The company's shares are down 25% year to date. \n\n\n  The company on Thursday posted a loss of $8.3 million, or 3 cents a share, compared with a loss of $426.1 million, or $1.44 a share, a year earlier. \n\n\n  Adjusted earnings came in at a loss of 12 cents a share, in line with estimates by analysts, according to FactSet. \n\n\n  Revenue remained steady year over year at $37.2 million. Analysts expected $39.9 million. \n\n\n  Instrument revenue, particularly for its Vega system for DNA sequencing, was lower than expected, said Chief Executive Christian Henry. The decrease in shipments of Vega systems was driven by lighter demand in the U.S., where academic funding remains under pressure. \n\n\n  The company's revenue in Asia-Pacific declined 16% year over year, Henry said, as Chinese service providers wait for the launch of its SPRQ-Nx product. \n\n\n  For 2026, the company expects revenue to range from $165 million to $175 million. Analysts expect $171.5 million. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 12:11 ET (16:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634517463","isCrawlerRequest":true}